In Vitro & In Vivo Diagnostic Substances
Standard Industrial Classification: SIC 2835
Industry Insider Sentiment Analysis
The In Vitro & In Vivo Diagnostic Substances sector (SIC 2835) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-22 23:31 | 2025-09-18 | ACHV | ACHIEVE LIFE SCIENCES, INC. | Oki Mark K | Officer | OPT+S | $2.92 | 50,060 | $146,175 | 127,940 |
| 2025-09-20 00:26 | 2025-09-17 | AWHL | Aspira Women's Health Inc. | cohen Jeffrey k | Director | BUY | $0.45 | 55,556 | $25,000 | 375,697 |
| 2025-09-19 23:05 | 2025-09-17 | AWHL | Aspira Women's Health Inc. | Fraser John D | Director | BUY | $0.45 | 16,389 | $7,375 | 566,393 |
| 2025-09-20 00:26 | 2025-09-17 | AWHL | Aspira Women's Health Inc. | SCHULER JACK W | 10% owner | BUY | $0.45 | 1,111,111 | $500,000 | 3,823,829 |
| 2025-09-15 16:00 | - | VNRX | VOLITIONRX LTD | Reynolds Cameron John | Director, Officer | BUY | $0.66 | 15,000 | $9,885 | 2,624,847 |
| 2025-09-08 23:39 | 2025-09-04 | ACHV | ACHIEVE LIFE SCIENCES, INC. | Xinos Jaime | Officer | OPT+S | $2.77 | 20,854 | $57,766 | 74,432 |
| 2025-09-08 23:59 | 2025-09-04 | ACHV | ACHIEVE LIFE SCIENCES, INC. | Wan Jerry | Officer | OPT+S | $2.77 | 14,070 | $38,974 | 32,694 |
| 2025-09-08 23:54 | 2025-09-04 | ACHV | ACHIEVE LIFE SCIENCES, INC. | KING THOMAS BRAXTON | Director | OPT+S | $2.77 | 139,858 | $387,407 | 315,142 |
| 2025-09-08 23:51 | 2025-09-04 | ACHV | ACHIEVE LIFE SCIENCES, INC. | JACOBS CINDY | Officer | OPT+S | $2.77 | 27,629 | $76,532 | 115,585 |
| 2025-08-27 00:00 | 2025-08-22 | IDXX | IDEXX LABORATORIES INC /DE | SZOSTAK M ANNE | Director | OPT+S | $647.33 | 2,187 | $1,415,700 | 262 |
| 2025-08-22 23:30 | 2025-08-20 | NTLA | Intellia Therapeutics, Inc. | CHASE WILLIAM J | Director | BUY | $10.03 | 100,000 | $1,003,000 | 134,693 |
| 2025-08-22 00:27 | 2025-08-19 | LNTH | Lantheus Holdings, Inc. | PATEL RAJIV A | SELL | $56.14 | 3,406,000 | $191,213,521 | 3,477,227 | |
| 2025-08-22 00:27 | 2025-08-19 | LNTH | Lantheus Holdings, Inc. | FARALLON PARTNERS L L C/CA | 10% owner | SELL | $56.14 | 3,406,000 | $191,213,521 | 3,477,227 |
| 2025-08-15 23:07 | 2025-08-13 | CLDX | Celldex Therapeutics, Inc. | Jimenez Freddy A. | Officer | SELL | $24.77 | 771 | $19,096 | 34,962 |
| 2025-08-15 23:33 | 2025-08-13 | LNTH | Lantheus Holdings, Inc. | Blanchfield Paul | Officer | SELL | $53.57 | 3,060 | $163,924 | 108,214 |
| 2025-08-15 01:01 | 2025-08-12 | IDXX | IDEXX LABORATORIES INC /DE | Erickson Michael G | Officer | SELL | $649.96 | 406 | $263,813 | 11,287 |
| 2025-08-14 00:17 | 2025-08-11 | IDXX | IDEXX LABORATORIES INC /DE | Hunt Nimrata | Officer | OPT+S | $656.53 | 1,200 | $787,840 | 16,807 |
| 2025-08-13 00:00 | 2025-08-08 | IDXX | IDEXX LABORATORIES INC /DE | Underberg Sharon E. | Officer | OPT+S | $651.60 | 5,450 | $3,551,220 | 6,156 |
| 2025-08-09 04:00 | 2025-08-06 | IDXX | IDEXX LABORATORIES INC /DE | Hunt Nimrata | Officer | OPT+S | $630.43 | 7,143 | $4,503,164 | 18,007 |
| 2025-08-09 03:37 | 2025-08-06 | IDXX | IDEXX LABORATORIES INC /DE | Lane Michael | Officer | OPT+S | $627.74 | 8,411 | $5,279,893 | 7,132 |
| 2025-08-09 03:38 | 2025-08-06 | IDXX | IDEXX LABORATORIES INC /DE | MAZELSKY JONATHAN JAY | Director, Officer | OPT+S | $631.98 | 29,260 | $18,491,641 | 83,311 |
| 2025-08-06 16:00 | - | VNRX | VOLITIONRX LTD | Innes Guy Archibald | Director | BUY | $0.64 | 78,125 | $50,000 | 966,814 |
| 2025-08-06 16:00 | - | VNRX | VOLITIONRX LTD | Reynolds Cameron John | Director, Officer | BUY | $0.64 | 78,125 | $50,000 | 2,609,847 |
| 2025-07-25 23:05 | 2025-07-23 | NTLA | Intellia Therapeutics, Inc. | Dulac Edward J III | Officer | SELL | $14.02 | 7,462 | $104,617 | 106,062 |
| 2025-07-03 23:11 | 2025-07-01 | NTLA | Intellia Therapeutics, Inc. | Clark Eliana | Officer | SELL | $9.82 | 1,022 | $10,036 | 95,369 |
| 2025-07-03 23:07 | 2025-07-02 | NTLA | Intellia Therapeutics, Inc. | Dube Michael P | Officer | SELL | $9.95 | 2,503 | $24,905 | 57,137 |
| 2025-07-03 00:50 | 2025-06-30 | NTLA | Intellia Therapeutics, Inc. | GOODMAN JESSE | Director | SELL | $9.40 | 3,094 | $29,068 | 24,359 |
| 2025-07-01 23:59 | 2025-06-27 | TKNO | Alpha Teknova, Inc. | DEMSKI MARTHA J | Director | SELL | $5.06 | 8,000 | $40,512 | 12,000 |
| 2025-06-17 23:31 | 2025-06-13 | LNTH | Lantheus Holdings, Inc. | Niedzwiecki Daniel | Officer | SELL | $78.74 | 6,000 | $472,440 | 87,057 |
| 2025-06-16 15:27 | - | VNRX | VOLITIONRX LTD | Reynolds Cameron John | Director, Officer | BUY | $0.59 | 12,500 | $7,373 | 2,331,722 |
| 2025-06-13 00:09 | 2025-06-12 | ICCC | IMMUCELL CORP /DE/ | Gathagan Bryan K. | Director | BUY | $6.32 | 1,000 | $6,320 | 1,000 |
| 2025-06-11 23:32 | 2025-06-09 | LNTH | Lantheus Holdings, Inc. | Marshall Robert J. Jr. | Officer | OPT+S | $83.00 | 39,773 | $3,301,294 | 88,860 |
| 2025-06-11 23:33 | 2025-06-09 | LNTH | Lantheus Holdings, Inc. | McHugh Julie | Director | SELL | $81.62 | 5,192 | $423,771 | 25,962 |
| 2025-06-09 23:34 | 2025-06-05 | LNTH | Lantheus Holdings, Inc. | Blanchfield Paul | Officer | SELL | $79.65 | 6,599 | $525,610 | 111,792 |
| 2025-06-09 23:34 | 2025-06-05 | LNTH | Lantheus Holdings, Inc. | Niedzwiecki Daniel | Officer | SELL | $79.65 | 6,000 | $477,900 | 93,057 |
| 2025-06-04 14:55 | - | VNRX | VOLITIONRX LTD | Innes Guy Archibald | Director | BUY | $0.54 | 20,000 | $10,772 | 888,689 |
| 2025-06-04 23:32 | 2025-06-02 | LNTH | Lantheus Holdings, Inc. | Heino Mary Anne | Director | SELL | $76.83 | 26,066 | $2,002,570 | 318,650 |
| 2025-05-24 00:00 | 2025-05-21 | IDXX | IDEXX LABORATORIES INC /DE | SZOSTAK M ANNE | Director | OPT+S | $512.97 | 2,306 | $1,182,917 | 1,801 |
| 2025-05-19 20:23 | - | VNRX | VOLITIONRX LTD | Micallef Jacob Vincent | Officer | BUY | $0.43 | 50,000 | $21,500 | 426,033 |
| 2025-05-19 19:43 | - | VNRX | VOLITIONRX LTD | Reynolds Cameron John | Director, Officer | BUY | $0.44 | 20,000 | $8,730 | 2,319,222 |
| 2025-05-15 00:00 | 2025-05-13 | IDXX | IDEXX LABORATORIES INC /DE | JUNIUS DANIEL M | Director | OPT+S | $506.41 | 2,683 | $1,358,697 | 3,304 |
| 2025-05-14 00:00 | 2025-05-09 | IDXX | IDEXX LABORATORIES INC /DE | Vandebroek Sophie V. | Director | OPT+S | $491.34 | 1,279 | $628,425 | 1,167 |
| 2025-05-12 21:30 | 2025-05-12 | NEOG | NEOGEN CORP | Gupta Aashima | Director | BUY | $6.25 | 16,000 | $99,987 | 21,917 |
| 2025-05-01 23:24 | 2025-04-29 | NTLA | Intellia Therapeutics, Inc. | Bhanji Muna | Director | SELL | $8.50 | 265 | $2,253 | 19,203 |
| 2025-04-25 23:32 | 2025-04-25 | NEOG | NEOGEN CORP | Woteki Catherine E | Director | BUY | $5.17 | 5,770 | $29,831 | 13,244 |
| 2025-04-25 21:45 | 2025-04-24 | NEOG | NEOGEN CORP | BOREL JAMES C | Director | BUY | $4.99 | 30,000 | $149,700 | 90,474 |
| 2025-04-24 18:18 | 2025-04-24 | NEOG | NEOGEN CORP | BOREL JAMES C | Director | BUY | $4.89 | 35,000 | $171,290 | 60,474 |
| 2025-04-24 22:34 | 2025-04-24 | NEOG | NEOGEN CORP | BOEHM WILLIAM T | Director | BUY | $5.24 | 5,000 | $26,175 | 36,214 |
| 2025-04-23 17:46 | 2025-04-23 | NEOG | NEOGEN CORP | Rocklin Amy M | Officer | BUY | $4.99 | 12,500 | $62,375 | 36,287 |
| 2025-04-22 18:46 | 2025-04-22 | NEOG | NEOGEN CORP | Tobin James P | Director | BUY | $4.73 | 10,000 | $47,268 | 37,474 |
Sector-Wide Insider Alpha
Analyzing insider movements across the In Vitro & In Vivo Diagnostic Substances sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2835) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in In Vitro & In Vivo Diagnostic Substances
Every transaction in the In Vitro & In Vivo Diagnostic Substances industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.